CTOs on the Move

Seismic Therapeutic

www.seismictx.com

 
We are The Machine Learning Immunology Company. Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics drug discovery and development process. Using our IMPACT™ platform, we are fully integrating machine learning with the key elements of biologics drug discovery – structural biology, protein engineering and translational immunology – to create optimized therapies for patients. Seismic Therapeutic has an emerging pipeline of novel approaches to address adaptive immune system dysregulation to treat autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.seismictx.com
  • 238 Main Street 5th Floor
    Cambridge, MA USA 02142
  • Phone: 617.294.9424

Executives

Name Title Contact Details

Similar Companies

DFM

DFM is a Morristown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NexImmune

NexImmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary AIM™ technology.

Urigen Pharmaceuticals

Urigen Pharmaceuticals is a Burlingame, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Abeona Therapeutics

Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Company`s multi-platform expertise across the manufacture, delivery, development, and discovery of novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company`s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM™ Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery. A robust and diverse pipeline is led by a novel gene-corrected cell therapy poised to enter Phase 3 in mid-2019 and complemented by one-time gene therapy candidates across four lysosomal storage diseases. Several preclinical discoveries are led by an emerging program in cystic fibrosis that uses the AIM vector platform and a capsid that has shown potential across inherited and acquired retinal diseases.

EcoSynthetix

EcoSynthetix is a Lansing, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.